EpiBone
Jersey City
About EpiBone
EpiBone is a pioneering regenerative medicine company at the forefront of bone and cartilage repair. Leveraging the power of stem cells, biomimicry, and 3D fabrication, they are developing a pipeline of innovative products with enormous potential to revolutionize orthopedic repair. Their lead product, a living, anatomically precise 3D bone graft, completed its Phase I/IIa clinical trial in August 2023. The rest of their pipeline focuses on cartilage repair, and includes an allogeneic osteochondral plug, whose IND was approved in July 2023. Their cartilage portfolio also includes an injectable cartilage filler that was partly funded by the Department of Defense.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $38.8M
- Last round: Series Unknown (Oct 2025)
- Website: epibone.com
- Phone: 2016300133
Industries & Categories
3D Technology, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/epibone-20223 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.